Gilead Sciences Inc., of Foster City, Calif., submitted a new drug application (NDA) to the FDA for a once-daily single tablet regimen that combines Gilead's emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical companies of New Brunswick, N.J.-based Johnson & Johnson.